<DOC>
	<DOCNO>NCT00024570</DOCNO>
	<brief_summary>IL13-PE38QQR oncology drug product consist IL13 ( interleukin-13 ) PE38QQR ( bacteria toxin ) . IL3-PE38QQR protein exhibit cell kill activity variety IL13 receptor-positive tumor cell line indicate may show therapeutic benefit . In reciprocal competition experiment , interaction IL13-PE38QQR IL13 receptor show highly specific human glioma cell . IL13-PE38QQR infuse two course 96 hour , eight week apart , directly malignant brain tumor patient determine dose drug patient tolerate . After , select dose studied give estimate response rate , response duration , time response , survival infuse dose IL13-PE38QQR recurrent malignant glioma .</brief_summary>
	<brief_title>Interstitial Infusion IL13-PE38QQR Cytotoxin Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicities maximum tolerated dose IL13-PE38QQR deliver continuous infusion malignant glioma 96 hour , two course eight week apart . II . Estimate response rate , response duration , time response , survival interstitial infusion IL13-PE38QQR recurrent malignant glioma . III . Describe toxicities interstitial infusion IL13-PE38QQR select dose . PROTOCOL OUTLINE : Patients expect receive two IL13-PE38QQR infusion 8-week interval . For course , drug infuse two catheter ; infusion rate hold constant 96-hour infusion . In Phase I , dose IL13-PE38QQR increase increase IL13-PE38QQR concentration stepwise fashion , hold infusion volume duration constant . Three patient treat dose level maximum tolerate dose ( MTD ) reach , additional three patient treat level . In Phase II , patient treat select MTD . PROJECTED ACCRUAL : In Phase I , 30 patient treat . In Phase II , 35 patient treat .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<criteria>Disease Characteristics Must surgery ( biopsy ) supratentorial brain tumor pathologic diagnosis malignant ( grade 3 4 ) glioma , include anaplastic astrocytoma , glioblastoma multiforme malignant mixed oligoastrocytoma . ( Note : If diagnosis dependent upon Day 0 biopsy , pathology must confirm prior start IL13PE38QQR infusion ) . Must receive cranial radiotherapy , tumor dose least 48 Gy , complete least 12 week prior study entry . Must radiographic evidence recurrent progressive supratentorial tumor compare previous study . The baseline tumor measurement must determine within 2 week prior study entry . The tumor must solid portion least 1.0 cm 5.0 cm maximum diameter . A maximum one satellite lesion permit , separate less 3 cm primary mass . Stereotaxic biopsy study entry must confirm presence glioma . Patient Characteristics Age 18 great . Karnofsky Performance Score must least 60 . Hematologic status : Absolute neutrophils least 1,500/mm^3 ; Hemoglobin least 10 gm/dL ; Platelets least 100,000/mm^3 ; PT &amp; PTT le equal upper limit normal . Hepatic Status : Transaminases 2.5 x upper limit normal ; Total Bilirubin 2.0 mg/dL . Must recover toxicity prior therapy ; least 6 week elapse since receive nitrosoureacontaining chemotherapy 3 week since receive chemotherapy . Must practice effective method birth control study . Must understand investigational nature study potential risk benefit , must sign informed consent . No patient two foci tumor , tumor cross midline , leptomeningeal tumor dissemination . No patient impend herniation , spinal cord compression , uncontrolled seizure . No patient receive localized antitumor therapy malignant glioma , either intralesional chemotherapy focal radiotherapy ( i.e . form stereotaxic RT brachytherapy ) . No patient receive concurrent chemotherapy another investigational agent . No patient prior concurrent malignancy . ( Patients curatively treated carcinomainsitu basal cell skin carcinoma OR free disease least 5 year eligible ) . Female patient must pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>neurosurgery , craniotomy</keyword>
	<keyword>convection-enhanced delivery</keyword>
	<keyword>CNS interstitial infusion</keyword>
	<keyword>recombinant toxin</keyword>
	<keyword>malignant glioma , recurrent</keyword>
	<keyword>catheter , stereotaxic</keyword>
	<keyword>intratumoral therapy</keyword>
	<keyword>positive pressure microinfusion</keyword>
</DOC>